CTI-118(CTI-118) - 在研适应症：新型冠状病毒感染_专利_临床

概要

基本信息

药物类型

生物药

别名

anti-COVID-19 therapeutics - Boston University School of Medicine/Cellics Therapeutics/University of California, San Diego

靶点-

作用方式

抑制剂

作用机制

病毒内化抑制剂

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

University of California San Diego

Boston University School of Medicine

在研机构

University of California San Diego

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 CTI-118 相关的临床结果

登录后查看更多信息

100 项与 CTI-118 相关的转化医学

登录后查看更多信息

100 项与 CTI-118 相关的专利（医药）

登录后查看更多信息

1

项与 CTI-118 相关的文献（医药）

1998-05-01·European Journal of Clinical Investigation3区 · 医学

Lack of relationship between the Pl^A1/Pl^A2 polymorphism of platelet glycoprotein IIIa and premature myocardial infarction

3区 · 医学

Article

作者: A. Maccagnani ; P. Cavallo-Perin ; M. Imazio ; A. Brusca ; S. Bergerone ; G. Macchia ; G. Gaschino ; L. Scaglione ; M. Di Leo ; M. Cassader ; R. Gambino ; G. Pagano

BackgroundThe PlA1/PlA2 polymorphism of the platelet glycoprotein IIIa has been variably associated with an increased risk of coronary thrombosis.MaterialsWe investigated the linkage between the PlA1/PlA2 polymorphism and the risk of myocardial infarction in 98 patients who suffered their first myocardial infarction at the age of 45 years or less and 98 well‐matched control subjects without coronary artery disease. Lipid parameters were measured using conventional methods of clinical chemistry; PlA genotypes were determined by polymerase chain reaction and restriction enzyme digestion.ResultsThere was no significant difference in the prevalence of PlA2‐positive genotypes (either PlA1/PlA2 or PlA2/PlA2) between patients and control subjects (χ2 = 0.66, d.f. = 1, P = 0.41).ConclusionsThese results suggest that the PlA2 polymorphism of the platelet glycoprotein IIIa does not contribute to the genetic susceptibility to premature myocardial infarction.

100 项与 CTI-118 相关的药物交易

登录后查看更多信息